ClinicalTrials.gg
CompletedNCT01152346Updated Jan 28, 2015

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

A Phase 1 interventional study of Azacitidine for Injection and Vidaza® in Myelodysplastic Syndrome, sponsored by Bioniche Pharma USA LLC. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-28.

Sponsored by Bioniche Pharma USA LLC · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
93rd of 126
19 · median 38
Started
2011
with 7 others
Phase 1
30 of 130
4 open now
Registered
38th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 93rd largest by enrollment of the 126 interventional ones that give a count, is one of 8 that started in 2011, is one of 30 in phase 1, and was the 38th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of the study is to determine the bioavailability of Azacitidine for Injection relative to Vidaza® in MDS patients under fasting conditions. The data will be evaluated statistically to determine if the products meet bioequivalence criteria.

Read the detailed description

This study is an open label, multi-center randomized, single dose, two-treatment, two-period, two-sequence, two-way cross-over, relative bioavailability study of Azacitidine for Injection for suspension use manufactured for Bioniche Pharma USA LLC compared with Vidaza® manufactured by Celgene Corporation in MDS patients under fasting conditions. Patients who are on a stable 75 mg/m2 dose of Vidaza will be randomized to study drug sequence Azacitidine on C1D1/ Vidaza® on C2D1 or Vidaza® on C1D1 / Azacitidine on C2D1. Randomization will be in a 2:2 ratio. Thirty-six (36) patients will be enrolled to ensure 28 evaluable patients. Patients will not be blinded to their treatment assignment.

After randomization, fasted patients will receive 1 dose of assigned study drug (either Azacitidine for Injection or Vidaza®) subcutaneously at a dose of 75 mg/m2 on C1D1. On Days 2-7, they will receive their normal Vidaza® treatment. Following a 21 day rest period, patients will cross over to receive the alternate treatment on C2D1 followed by their normal Vidaza®) treatment on Cycle 2 Days 2-7. The Final Patient Visit will be conducted 7 days following the last dose of Vidaza®.

The total duration of the study for each patient will be up to 56 days including the Screening period and Post Study Visit.

03

Conditions studied

  • Myelodysplastic Syndrome

Keywords

  • Bioequivalence
  • Myelodysplastic Syndrome
  • MDS
  • Azacitidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients with age >18 years.
  • Patients with Myelodysplastic Syndrome (MDS) placed on Vidaza® according to the Marketing Authorization issued in the country in which the clinical study is being conducted (i.e., in the US, patients with any of the following French-American-British ( FAB) subtypes: Anemia (RA), Refractory Anemia with Ringed Sideroblasts (RARS), (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), Refractory Anemia with Excess Blasts (RAEB), Refractory Anemia with Excess Blasts in Transformation (RAEB-T) and Chronic Myelomonocytic Leukemia (CMMoL); in France, subjects who are not eligible for hematopoietic stem cell transplantation: with intermediate -2 and high-risk myelodysplastic syndromes according to the International Prognostic Scoring System (IPSS) or chronic myelomonocytic leukemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder) and who currently receive Vidaza at 75 mg/m2;
  • Patient > 6 months.
  • Patients with performance status of 0 - 2 as per Scale.
  • Patients with Total \< 1.5 x ; /AST \< 2 x ULN, Serum Creatinine \< 1.5 ULN, Serum Bicarbonate > 19 mEq/L.
  • Patients who have signed the Form.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of alcoholism or drug addiction (during past 2 years)
  • Patients with severe hepatic impairment, impaired renal function, and any condition which in the Investigator's opinion would be or would interfere with absorption of the study drug.
  • Patients whose clinical laboratory test values are outside the reference range may be re-tested at the discretion of the Investigator. If the clinical values are outside the range on re-testing, the patient will not be eligible to participate in the study unless the Investigator deems the result not to be significant.
  • Patients with any other active within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.
  • Patients who have a history of allergic responses to the class of drug being tested.
  • Patients with to Mannitol.
  • Patients should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study drug. Patients should not have had any transfusion of blood products for at least 7 days prior.
  • Patients who have taken any drug within thirty (30) days prior to the first dosing of the study.
  • Female patients who are pregnant, breast-feeding, or who are likely to become pregnant during the study. Female patients of child bearing potential will be instructed to either abstain from sexual intercourse or use an acceptable method of during the course of the study and for 3 months afterward. Male patients or their female partners should also use an acceptable method of birth control.
  • Any patient whom the Investigator believes will not be a good candidate for the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Other
    ARM 1

    Sequence- Azacitidine followed by Vidaza®

    Drug: Azacitidine for Injection · Drug: Vidaza®

  • Other
    ARM 2

    Sequence-Vidaza® followed by Azacitidine

    Drug: Azacitidine for Injection · Drug: Vidaza®

Interventions

  • 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment

  • 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment

06

What researchers measure

Primary outcomes

  1. Measurement of Azacitidine in Plasma Samples for Determination of Cmax, AUC0-t, and AUC0-Inf

    Pharmacokinetic samples will be collected pre-dose and at 12 timepoints post-dose for determination of the level of azacitidine. The relative bioavailability of test to reference drug will be evaluated. If the Cmax, AUC0-t and AUC0-inf 90% confidence intervals for the geometric mean ratio all lie within 80-125% for Azacitidine then bioequivalence is concluded.

    Time frame: 13 timepoints from pre-dose to 8 hours post dose

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Safety will be assessed through monitoring of adverse events and laboratory measures.

    Time frame: Throughout study

07

Study locations

13 sites
  • Pacific Cancer Medical Center Inc.
    Anaheim, California 92801, United States
  • Wilshire Oncology Medical Group
    Corona, California 92879, United States
  • California Cancer Associates
    Fresno, California 93720, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Service d'hématologie clinique Hôpital Avicenne
    Bobigny cedex, 93009, France
  • CHU de Brest- Hôpital Morvan
    Brest, 29609, France
  • Centre Hospitalier Lyon Sud
    Lyon, 69495, France
  • Hôpital Archet 1
    Nice, 06200, France
  • Hôpital Haut-Lévêque
    Pessac, 33604, France
  • CH Annecy
    Pringy, 74374, France
  • CHU Purpan
    Toulouse, 31059, France
  • Centre régional de cancérologie Henry-Kaplan Service d'Hématologie et thérapie cellulaire
    Tours, 37000, France
  • Service d'hématologie et de médecine interne CHU de Nancy Hôpital de Brabois
    Vandoeuvre, 54511, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Dec 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2010
First posted
Jun 29, 2010
Start
Apr 2011
Primary completionActual
Dec 2012
CompletionActual
May 2013
Last update
Jan 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01152346
Lead sponsor
Bioniche Pharma USA LLC
Responsible party
Sponsor
First posted
Jun 29, 2010
Start date
Apr 2011
Primary completion
Dec 2012
Completion
May 2013
Last update
Jan 28, 2015

Study contacts

Pierre FENAUX, MD Professor
study chair · Service d'hématologie clinique- Hôpital Avicenne
Emmanuel GYAN, MD
principal investigator · Centre régional de cancérologie Henry-Kaplan Service d'Hématologie et thérapie cellulaire-Hôpital Bretonneau
Agnès-Paule GUERCI-BRESLER, MD
principal investigator · Service d'hématologie et de médecine interne-Hôpital de Brabois
Jean-Richard Eveillard, MD
principal investigator · CHU de Brest- Hôpital Morvan
Odile BEYNE-RAUZY, MD Professor
principal investigator · University Hospital, Toulouse
Laurence LEGROS, MD
principal investigator · Hôpital Archet 1
Mauricette MICHALLET, MD Professor
principal investigator · Hôpital Edouard Herriot
Krimo Bouabdallah, MD
principal investigator · Hôpital Haut-Lévêque
Pascal Cony-Makhoul, MD
principal investigator · CH Annecy
Manjesh Lingamurthy, MD
principal investigator · Holy Cross Hospital
Steven Hager, MD
principal investigator · California Cancer Associates
Misagh Karimi, MD
principal investigator · Wilshire Oncology Medical Group
Veena Charu, MD
principal investigator · Pacific Cancer Medical Center Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion